AHA 2022 Paul Kalra shares the results of the IRONMAN study that investigated the effects of ferric derisomaltose on cardiovascular events in patients with iron deficiency and HF.
AHA 2022 The ISCHEMIA-EXTEND study showed that after a median follow-up of 5.7 years an initial invasive strategy compared with an initial conservative strategy in patients with chronic coronary disease resulted in no difference in all-cause mortality, lower risk of CV mortality, and higher risk of non-CV mortality.
AHA 2022 High CV risk patients in ORION-1 were invited to participate in open-label extension study with inclisiran -the ORION-3 study. What is the 4-year long-term efficacy and safety of inclisiran in these patients?
AHA 2022 The endothelin pathway may present a new target to reduce blood pressure in patients with resistant hypertension. In the PRECISION trial, BP lowering effects of aprocitentan, a dual endothelin A and B receptor antagonist, were investigated.
AHA 2022 The phase 2 OCEAN(a)-DOSE study showed that olpasiran dosed 75 mg or higher every 12 weeks reduces Lp(a) by >95% in patients with elevated Lp(a) and established ASCVD.
AHA 2022 The SPYRAL HTN-ON MED pilot trial was expanded resulting in a larger cohort of patients on hypertensive medication who underwent radiofrequency renal denervation (RDN) or sham treatment. What was the change in systolic ABPM after 6 months between the two groups?
AHA 2022 In patients with highly symptomatic obstructive HCM who were referred for septal reduction therapy (SRT), mavacamten reduced the need for SRT at 32 weeks.
AHA 2022 Prof. Mebazaa explains why patients and healthcare providers will love the STRONG-HF regimen of quick uptitration of HF therapies in hospitalized acute HF patients ready for discharge.
In hospitalized acute HF patients ready for discharge, rapid uptitration of medication with close follow-up was safe and led to fewer HF hospital readmissions or deaths compared with usual care.
AHA 2022 An RCT showed that low-dose statin is superior in lowering LDL-c compared with placebo and 6 different dietary supplements. Moreover, dietary supplements did not significantly reduce LDL-c compared with placebo.
AHA 2022 The RESPECT-EPA study evaluated the effects of highly purified EPA in combination with statin therapy on CV events in Japanese patients with chronic CAD.
AHA 2022 "We feel that a precision pathway -consisting of deferred testing by quantitative analysis and CCTA with selective FFR- is a preferred strategy in stable patients with suspected CAD", says Prof. Douglas.